Treatment of acute exacerbations of chronic bronchitis: Antibiotic therapy

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Acute exacerbation of chronic bronchitis (AECB) is a condition associated with increased morbidity and mortality. Bacterial infections are the most frequent cause of exacerbations. The most common bacterial etiologies include Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumonia. The diagnosis of AECB is often based on the clinical presentation, but microbiological assessment, including Gram stain and sputum culture should be done. Antibiotic therapy should be used in patients with the following characteristics: underlying lung disease, frequent exacerbations, and comorbid conditions. Penicillins, erythromycin, β-lactamase inhibitors, and trimethoprimsulfamethoxazole have been the preferred antibiotics. However, because of the increasing prevalence of resistance among respiratory pathogens, mainly the production of β-lactamase by H. influenzae and M. catarrhalis, and the emergence of multidrug-resistant S. pneumonia, new generation macrolides and fluoroquinolones should be the first line of treatment in selected patients. These drugs have increased efficacy and safety.

Original languageEnglish (US)
Pages (from-to)97-106
Number of pages10
JournalSeminars in Respiratory and Critical Care Medicine
Volume21
Issue number2
StatePublished - 2000

Fingerprint

Moraxella (Branhamella) catarrhalis
Chronic Bronchitis
Haemophilus influenzae
Streptococcus pneumoniae
Anti-Bacterial Agents
Fluoroquinolones
Macrolides
Erythromycin
Sputum
Bacterial Infections
Penicillins
Lung Diseases
Disease Progression
Morbidity
Safety
Mortality
Therapeutics
Pharmaceutical Preparations
Gram's stain

Keywords

  • Acute exacerbation of chronic bronchitis
  • Antibiotics
  • Cephalosporins
  • Fluoroquinolones
  • Marcrolides
  • Penicillin s

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Pulmonary and Respiratory Medicine
  • Critical Care

Cite this

@article{e97cc760f5734c29a8b615d23f0d22cb,
title = "Treatment of acute exacerbations of chronic bronchitis: Antibiotic therapy",
abstract = "Acute exacerbation of chronic bronchitis (AECB) is a condition associated with increased morbidity and mortality. Bacterial infections are the most frequent cause of exacerbations. The most common bacterial etiologies include Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumonia. The diagnosis of AECB is often based on the clinical presentation, but microbiological assessment, including Gram stain and sputum culture should be done. Antibiotic therapy should be used in patients with the following characteristics: underlying lung disease, frequent exacerbations, and comorbid conditions. Penicillins, erythromycin, β-lactamase inhibitors, and trimethoprimsulfamethoxazole have been the preferred antibiotics. However, because of the increasing prevalence of resistance among respiratory pathogens, mainly the production of β-lactamase by H. influenzae and M. catarrhalis, and the emergence of multidrug-resistant S. pneumonia, new generation macrolides and fluoroquinolones should be the first line of treatment in selected patients. These drugs have increased efficacy and safety.",
keywords = "Acute exacerbation of chronic bronchitis, Antibiotics, Cephalosporins, Fluoroquinolones, Marcrolides, Penicillin s",
author = "Anzueto, {Antonio R}",
year = "2000",
language = "English (US)",
volume = "21",
pages = "97--106",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "2",

}

TY - JOUR

T1 - Treatment of acute exacerbations of chronic bronchitis

T2 - Antibiotic therapy

AU - Anzueto, Antonio R

PY - 2000

Y1 - 2000

N2 - Acute exacerbation of chronic bronchitis (AECB) is a condition associated with increased morbidity and mortality. Bacterial infections are the most frequent cause of exacerbations. The most common bacterial etiologies include Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumonia. The diagnosis of AECB is often based on the clinical presentation, but microbiological assessment, including Gram stain and sputum culture should be done. Antibiotic therapy should be used in patients with the following characteristics: underlying lung disease, frequent exacerbations, and comorbid conditions. Penicillins, erythromycin, β-lactamase inhibitors, and trimethoprimsulfamethoxazole have been the preferred antibiotics. However, because of the increasing prevalence of resistance among respiratory pathogens, mainly the production of β-lactamase by H. influenzae and M. catarrhalis, and the emergence of multidrug-resistant S. pneumonia, new generation macrolides and fluoroquinolones should be the first line of treatment in selected patients. These drugs have increased efficacy and safety.

AB - Acute exacerbation of chronic bronchitis (AECB) is a condition associated with increased morbidity and mortality. Bacterial infections are the most frequent cause of exacerbations. The most common bacterial etiologies include Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumonia. The diagnosis of AECB is often based on the clinical presentation, but microbiological assessment, including Gram stain and sputum culture should be done. Antibiotic therapy should be used in patients with the following characteristics: underlying lung disease, frequent exacerbations, and comorbid conditions. Penicillins, erythromycin, β-lactamase inhibitors, and trimethoprimsulfamethoxazole have been the preferred antibiotics. However, because of the increasing prevalence of resistance among respiratory pathogens, mainly the production of β-lactamase by H. influenzae and M. catarrhalis, and the emergence of multidrug-resistant S. pneumonia, new generation macrolides and fluoroquinolones should be the first line of treatment in selected patients. These drugs have increased efficacy and safety.

KW - Acute exacerbation of chronic bronchitis

KW - Antibiotics

KW - Cephalosporins

KW - Fluoroquinolones

KW - Marcrolides

KW - Penicillin s

UR - http://www.scopus.com/inward/record.url?scp=0033911531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033911531&partnerID=8YFLogxK

M3 - Article

C2 - 16088723

AN - SCOPUS:0033911531

VL - 21

SP - 97

EP - 106

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 2

ER -